In general, practices and health systems don’t do a good job of integrating technology into practice, partly because most of the technology they use isn’t well suited to their needs, explained Charles Saunders, MD, CEO of Integra Connect.
In general, practices and health systems don’t do a good job of integrating technology into practice, partly because most of the technology they use isn’t well suited to their needs, explained Charles Saunders, MD, CEO of Integra Connect.
Transcript
How do practices need to use information technology to succeed in the new value-based care environment?
Well, the Oncology Care Model has certain requirements; one of those is the use of an ONC [Office of the National Coordinator]-certified electronic health record. Another one is data-driven quality improvement programs, as well as care navigation, and use of evidence-based care paths and creation and management to an Oncology Care Model care plan. And, so, technology is used for all of those requirements, and I would say the trickiest part of it, however, is curating the data and determining and calculating the performance measures required for the Oncology Care Model.
How well are practices and health systems doing with integrating new technology into practice?
Well, generally, not very well. In most cases, they use an electronic health record (EHR), most of the EHRs out there are not actually suited for the Oncology Care Model. They don’t, oftentimes, capture the data that is necessary to do the calculations, and they don’t actually provide support or enablement for managing care or team-based care management. They’re generally for documenting an episode of care and administering chemotherapy. So, they weren’t really designed for that purpose.
Additionally, the ability to integrate and curate the data is proving to be very difficult, and, in many cases, if not all, some level of manual data curation is necessary.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More